Adherence to antiretroviral therapy in patients enrolled in a comprehensive care program in Cambodia: a 24-month follow-up assessment
AffiliationInserm U912, Economic and Social Sciences, Health Systems and Societies, Marseille, France; Infectious Disease Department, Khmero-Sovietic Friendship Hospital, Phnom Penh, Cambodia; Médecins Sans Frontières, Paris, France; Epicentre, Paris, France; Clinical Immunology Department, Bicêtre Hospital, Kremlin Bicêtre, France; Immunological Department, Georges Pompidou, European Hospital, Paris France
MetadataShow full item record
AbstractBACKGROUND: The long-term maintenance of antiretroviral therapy (ART) remains an important issue, especially in limited-resource settings where additional barriers exist. A cross-sectional study was performed 24 months after ART initiation for patients treated in Cambodia in order to estimate the prevalence and identify determinants of non-adherence. METHODS: Adults receiving ART for 24 +/- 2 months were considered eligible for the study. Self-reported non-adherence was defined according to an algorithm based on six items. The questionnaire also assessed ART-related side effects and HIV disclosure. HIV-1 RNA plasma viral load was measured using real-time PCR. Multivariate rare events logistic regression analysis was used to identify independent factors associated with non-adherence. RESULTS: A total of 346 patients participated in the study. At 24 months, 95% of patients were adherent, 80% had HIV RNA <40 copies/ml and 75% had CD4+ T-cell counts >200 cells/mm3. Virological success was significantly higher in adherent patients than in non-adherent patients (81% versus 56%, P=0.021). Living in a rural area, limited HIV disclosure and perceived lipodystrophy were independently associated with non-adherence. CONCLUSIONS: At 24 months, adherence to ART was high and explained positive virological outcomes. In order to maintain adherence and long-term virological benefits, special attention should be given to patients living in rural areas, those with lipodystrophy-related symptoms and others who express difficulties disclosing their condition to close family members.
- Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance.
- Authors: Masquelier B, Pereira E, Peytavin G, Descamps D, Reynes J, Verdon R, Fleury H, Garraffo R, Chêne G, Raffi F, Brun-Vézinet F, APROCO/COPILOTE Study Group.
- Issue date: 2005 May
- Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
- Authors: Soria A, Porten K, Fampou-Toundji JC, Galli L, Mougnutou R, Buard V, Kfutwah A, Vessière A, Rousset D, Teck R, Calmy A, Ciaffi L, Lazzarin A, Gianotti N
- Issue date: 2009
- Triple-class HIV antiretroviral therapy failure in an Australian primary care setting.
- Authors: Bloch M, Farris M, Tilden D, Gowers A, Cunningham N
- Issue date: 2010 Mar
- Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy.
- Authors: Galli M, Ridolfo AL, Adorni F, Cappelletti A, Morelli P, Massetto B, Piazza M, Gianelli E, Vaccarezza M, Gervasoni C, Moroni M
- Issue date: 2003 Aug
- Consequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group protocol 370.
- Authors: Ickovics JR, Cameron A, Zackin R, Bassett R, Chesney M, Johnson VA, Kuritzkes DR, Adult AIDS Clinical Trials Group 370 Protocol Team.
- Issue date: 2002 Sep